TP53 and myelodysplastic syndrome: TP53 alterations are discovered in about 5–10% of MDS patients [34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92], with the majority of cases having “multi-hit” involvement with more than one genomic and/or chromosome 17 abnormalities and fewer alterations in other genes [92].